Genomic Health, Inc., will present results from nine different studies of Oncotype DX®, a genomic-based diagnostic test, in prostate, breast, and renal cancers at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid.
Included in the program is the first presentation of relevant positive results from an additional large independent clinical validation study of Oncotype DX as a prostate cancer test, which predicts disease aggressiveness in men with low risk disease. This study was developed in collaboration with the Center for Prostate Disease Research, Rockville, MD, and shows the ability of Oncotype DX to predict an increase in prostate-specific antigen (PSA) following surgery, establishing it as a predictor of recurrence from the biopsy, as previously demonstrated in a validation study performed at the University of California, San Francisco (UCSF).
Overall, Genomic Health will present its portfolio of successful approaches towards a better understanding in tumor biology of different cancer types, emphasizing the additional clinical validation of the Oncotype DX prostate cancer test and showing its ability to predict both actionable and long term clinical endpoints related to disease aggressiveness.
Moreover, additional evidence of the practice-changing impact of the Oncotype DX test in breast cancer, already shown to predict the probability of chemotherapy advantage and cancer recurrence in invasive breast cancer, along with the probability of recurrence in ductal carcinoma in situ (DCIS) will be demonstrated. Furthermore, the importance of Oncotype DX in assessing multiple, relevant, biological pathways to predict tumor behavior will also be highlighted.
The poster presented in ESMO regarding prostate cancer is titled “A prospectively-designed study to determine the association of a 17-gene genomic prostate score with recurrence following surgery for localized prostate cancer (PCa),” and will be presented by Dr. Jennifer Cullen, Center for Prostate Disease Research, Department of Defense, Rockville.